The global demand for Non-small Cell Lung Cancer Market is presumed to reach the market size of nearly USD XX MN by 2030 from USD XX MN in 2022 with a CAGR of 10.29% under the study period 2023 - 2030.
Non-small cell lung cancer (NSCLC) accounts for close to 85% to 90% of all lung cancer cases. It originates in the tissues of the lungs and is characterized by the abnormal growth and proliferation of cells in the lung tissue, leading to the formation of tumors. NSCLC is distinct from small cell lung cancer (SCLC), which is a more aggressive and less common type of lung cancer.
The non-small cell lung cancer market is driven by a constellation of factors resulting from the disease's prevalence, scientific advancements, and changing treatment paradigms. NSCLC's high incidence underscores the need for effective therapies, spurring research and innovation. Genetic research has enabled targeted therapies that tailor treatments to specific mutations, while immunotherapy has shown promise in improving patient outcomes. Personalized medicine and advances in diagnostics contribute to early detection and intervention. Government initiatives, advocacy efforts, and ageing populations further propel the NSCLC market. Technological progress in diagnostics and treatment options, coupled with patient-centric care approaches, enhances overall care quality. Globalization ensures information and treatments are accessible, while education campaigns heighten awareness and encourage early detection. The NSCLC market's growth is a collaborative effort, combining medical advances, research endeavours, and a shared goal of improving patient well-being and survival rates.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of non-small cell lung cancer. The growth and trends of non-small cell lung cancer industry provide a holistic approach to this study.
This section of the non-small cell lung cancer market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Cancer Type
By Treatment
This section covers the regional outlook, which accentuates current and future demand for the Non-small Cell Lung Cancer market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Non-small Cell Lung Cancer market include F. Hoffmann-La Roche, AstraZeneca, Bristol-Myers Squibb, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Bayer Healthcare, Eli Lilly and Company, and GlaxoSmithKline. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . NON-SMALL CELL LUNG CANCER – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Cancer Type
3.7.2 Market Attractiveness Analysis By Treatment
3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL NON-SMALL CELL LUNG CANCER MARKET ANALYSIS BY CANCER TYPE
5.1 Overview by Cancer Type
5.2 Historical and Forecast Data
5.3 Analysis by Cancer Type
5.4 Squamous Cell Carcinoma Historic and Forecast Sales by Regions
5.5 Adenocarcinoma Historic and Forecast Sales by Regions
5.6 Large-cell Carcinoma Historic and Forecast Sales by Regions
6 . GLOBAL NON-SMALL CELL LUNG CANCER MARKET ANALYSIS BY TREATMENT
6.1 Overview by Treatment
6.2 Historical and Forecast Data
6.3 Analysis by Treatment
6.4 Chemotherapy Historic and Forecast Sales by Regions
6.5 Targeted Therapy Historic and Forecast Sales by Regions
6.6 Immunotherapy Historic and Forecast Sales by Re ...